Please login to the form below

Not currently logged in
Email:
Password:

Abbott agrees $400m chronic disease deal with Reata

Will collaborate on oral treatments for pulmonary and central nervous system disorders and in immunology

Abbott has signed a major co-development deal for a portfolio of molecules that target pulmonary and central nervous system disorders, as well as immunology conditions.

The pharma company will make a one-off payment of $400m to Texas, US-based Reata Pharmaceuticals for its second-generation oral antioxidant inflammation modulators (AIMs).

"This deal helps Reata advance new molecules into clinical development in multiple important diseases and enables our company to build a global commercial presence," explained the company's CEO Warren Huff.

The two companies will develop the molecules across a range of therapy areas, and share costs and profits equally for all developed AIMs, with the exception of rheumatoid arthritis and select other autoimmune diseases.

For these conditions, Abbott will take 70 per cent of costs and profits, while Reata will take 30 per cent.

AIMs are thought to be beneficial in the treatment of certain chronic diseases by promoting the production of a range of range of antioxidant, detoxification, and anti-inflammatory genes as well helping to control the production of pro-inflammatory enzymes. It does this though activating the protein Nrf2 which plays a role in both aspects of treatment.

Dr John Leonard, senior vice president of pharmaceuticals research and development at Abbott, said: "Accumulating data has established the potential for antioxidant inflammation modulators in neuroscience and immunology, and we look forward to expanding our knowledge through further research."

Abbott and Reata already have an existing partnership, with Abbott holding exclusive rights to develop and commercialise Reata's lead AIM compound, bardoxolone methyl, outside of the US. The new deal will not affect the terms of this agreement.

It is expected that the first compound in the new collaboration will enter human clinical trials in 2012.

13th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell - Cake

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics